Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 16, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 645,000 ordinary shares of 25 pence each.
- Purchase Price: 1,544.13 pence per share.
- Treasury Shares Held: 151,814,678 shares (post-transaction).
- Shares in Issue: 5,821,034,378 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed this purchase on March 16, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (645,000 shares at 1,544.13 pence) against the company's cash position in broader financial reports.
- Confirm the total number of shares in issue (5,821,034,378) and the growing Treasury holding (151,814,678) to assess potential dilution or capital return strategies.
- Note that this filing is a transactional report and does not replace quarterly or annual financial performance data.